PMID- 7884953
OWN - NLM
STAT- MEDLINE
DCOM- 19950412
LR  - 20220330
IS  - 0098-7484 (Print)
IS  - 0098-7484 (Linking)
VI  - 273
IP  - 12
DP  - 1995 Mar 22-29
TI  - Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at 
      risk for familial Alzheimer disease.
PG  - 942-7
AB  - OBJECTIVE: Cerebral parietal hypometabolism and left-right asymmetry occur early 
      in the course of Alzheimer disease (AD), and the apolipoprotein E type 4 allele 
      (APOE epsilon 4) is a risk factor for familial AD. To determine if APOE epsilon 4 
      is associated with lowered brain function in nondemented relatives at risk for 
      familial AD, we studied 12 relatives with APOE epsilon 4 and 19 relatives without 
      APOE epsilon 4. We also compared them with seven patients with probable AD. 
      DESIGN: After grouping subjects according to diagnosis and genotype, brain 
      function measures were compared among groups. SETTING: University medical center. 
      PATIENTS: At risk subjects had mild memory complaints, normal cognitive 
      performance, and at least two relatives with AD. Subjects with APOE epsilon 4 did 
      not differ from those without APOE epsilon 4 in mean age at examination (56.4 vs 
      55.5 years) or in neuropsychological performance (mean Mini-Mental State 
      Examination score, 28.8 vs 29.3). MAIN OUTCOME MEASURES: Cerebral glucose 
      metabolism was measured using positron emission tomography and fludeoxyglucose F 
      18. RESULTS: Parietal metabolism was significantly lower and left-right parietal 
      asymmetry was significantly higher in at-risk subjects with APOE epsilon 4 
      compared with those without APOE epsilon 4. Patients with dementia had 
      significantly lower parietal metabolism than did at-risk subjects with APOE 
      epsilon 4. CONCLUSIONS: These results suggest that the inheritance of APOE 
      epsilon 4 is associated with reduced cerebral parietal metabolism and increased 
      asymmetry in non-demented relatives at risk for probable AD. Longitudinal study 
      will determine if glucose metabolic measures provide a means to monitor 
      experimental treatment responses during the early phases of the disorder.
FAU - Small, G W
AU  - Small GW
AD  - Department of Psychiatry, University of California, Los Angeles School of 
      Medicine.
FAU - Mazziotta, J C
AU  - Mazziotta JC
FAU - Collins, M T
AU  - Collins MT
FAU - Baxter, L R
AU  - Baxter LR
FAU - Phelps, M E
AU  - Phelps ME
FAU - Mandelkern, M A
AU  - Mandelkern MA
FAU - Kaplan, A
AU  - Kaplan A
FAU - La Rue, A
AU  - La Rue A
FAU - Adamson, C F
AU  - Adamson CF
FAU - Chang, L
AU  - Chang L
AU  - et al.
LA  - eng
GR  - U24 AG021886/AG/NIA NIH HHS/United States
GR  - 1R29 MH46424/MH/NIMH NIH HHS/United States
GR  - AG05128/AG/NIA NIH HHS/United States
GR  - AG10123/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Apolipoprotein E4)
RN  - 0 (Apolipoproteins E)
RN  - 0 (Fluorine Radioisotopes)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Alleles
MH  - Alzheimer Disease/*genetics/*metabolism/physiopathology
MH  - Analysis of Variance
MH  - Apolipoprotein E4
MH  - *Apolipoproteins E/genetics/physiology
MH  - Brain/diagnostic imaging/*metabolism/pathology/physiology
MH  - Deoxyglucose/analogs & derivatives
MH  - Family
MH  - Female
MH  - Fluorine Radioisotopes
MH  - Fluorodeoxyglucose F18
MH  - Genotype
MH  - Glucose/*metabolism
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Models, Theoretical
MH  - Neuropsychological Tests
MH  - Risk Factors
MH  - Tomography, Emission-Computed
EDAT- 1995/03/22 00:00
MHDA- 1995/03/22 00:01
CRDT- 1995/03/22 00:00
PHST- 1995/03/22 00:00 [pubmed]
PHST- 1995/03/22 00:01 [medline]
PHST- 1995/03/22 00:00 [entrez]
PST - ppublish
SO  - JAMA. 1995 Mar 22-29;273(12):942-7.